6:21 PM
 | 
May 28, 2009
 |  BC Extra  |  Top Story

Exelixis gains on sanofi-aventis deal

Shares of Exelixis Inc. (NASDAQ:EXEL) rose $0.85 (19%) to $5.36 on Thursday after the biotech granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to XL147 and XL765. The oral phosphoinositide...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >